Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer
- 28 January 2021
- journal article
- research article
- Published by S. Karger AG in Dermatology
- Vol. 237 (6), 929-933
- https://doi.org/10.1159/000513233
Abstract
Background: Epidermal growth factor receptor (EGFR) inhibitors are routinely used in advanced non-small-cell lung cancer (NSCLC) harboring EGFR mutations. However, their use is associated with gastrointestinal and cutaneous toxicities, including acneiform eruptions, pruritus, xerosis, nail and hair changes. Aside from reducing patients’ quality of life, such cutaneous reactions have a considerable impact on the oncologic treatment given that dose reduction or even drug discontinuation may be necessary, especially for the severe forms. Objectives: To assess the incidence, impact on treatment and management of EGFR inhibitor-related cutaneous reactions in patients with NSCLC. Methods: We conducted a prospective observational study on 87 consecutive patients with advanced NSCLC treated with EGFR-tyrosine kinase inhibitors from January to December 2019. Patients who developed mucocutaneous reactions were evaluated and treated by both oncologists and dermatologists, and underwent dermatologic follow-up until resolution of the cutaneous reaction. Demographic and clinical data were collected for each patient, and the severity of the cutaneous reaction was graded using the Common Terminology Criteria for Adverse Events. Results: Seventy-one patients (81.6%) developed cutaneous reactions. The number of cutaneous reactions per patient was 1 in 37%, 2 in 41% and 3 or more in 22%. The most common cutaneous reactions included acneiform eruptions (56.3%), xerosis ± asteatotic eczema (48.3%), nail changes (39.1%), mucositis (29.9%), pruritus (24.1%) and hair changes (12.6%). Afatinib was associated with a higher rate of nail changes and mucositis (p < 0.01 and p < 0.005, respectively) compared to other agents, while no patient-related predictive factors were identified. Dose reduction was performed in 18% of patients. Multidisciplinary management involving dermatologists allowed to resume the drug in all patients who had discontinued it due to the cutaneous reactions. Conclusions: A multidisciplinary approach to EGFR inhibitor-related cutaneous reactions is advantageous and can reduce the need to discontinue oncologic treatment.Keywords
This publication has 17 references indexed in Scilit:
- Management of Skin Reactions During Cetuximab Treatment in Association With Chemotherapy or RadiotherapyAmerican Journal of Clinical Oncology, 2016
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancerJournal of the American Academy of Dermatology, 2014
- Epidermal growth factor receptor signalling in keratinocyte biology: implications for skin toxicity of tyrosine kinase inhibitorsArchives of Toxicology, 2014
- Adverse skin reactions during treatment with cetuximab plus radiotherapy: Multidisciplinary approach to minimize radio-chemotherapy interruptionJournal of Dermatological Treatment, 2014
- Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral ClinicAmerican Journal of Clinical Dermatology, 2013
- Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicitiesSupportive Care in Cancer, 2011
- Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitorsInternational Journal of Dermatology, 2011
- Chemotherapeutic agents and the skin: An updateJournal of the American Academy of Dermatology, 2008
- Cutaneous side effects of epidermal growth factor receptor inhibitors: Clinical presentation, pathogenesis, and managementJournal of the American Academy of Dermatology, 2007
- Mechanisms of cutaneous toxicities to EGFR inhibitorsNature Reviews Cancer, 2006